Abstract | OBJECTIVES: METHODS: We compared the incidence of PVT, postsurgical bleeding, and thrombotic complications in patients undergoing TPIAT between 2001 and 2018 at the University of Minnesota who received either unfractionated heparin (UFH) or enoxaparin for postoperative PVT prophylaxis. Six-month and 1-year graft function was compared between patients who developed PVT and those who did not. RESULTS: Twelve patients (6.6%) developed a PVT, which resolved by 6 months after TPIAT in 10 patients. There was no statistically significant difference in PVT rate between patients who received UFH or enoxaparin for prophylaxis (P = 0.54). Patients who received enoxaparin developed other thrombotic complications more often (6% vs 0%, P = 0.02). Islet graft function did not differ in patients who developed PVT versus those who did not. CONCLUSIONS: There was no difference between enoxaparin or UFH prophylaxis in preventing PVT, but there may be a higher incidence of other thrombotic complications with enoxaparin. In the setting of routine screening and anticoagulation therapy, PVT is a self-limited process.
|
Authors | Alexandria J Robbins, Mariya E Skube, Melena D Bellin, Ty B Dunn, Scott A Chapman, K Louise Berry, Elizabeth Lusczek, Gregory J Beilman |
Journal | Pancreas
(Pancreas)
2019 Nov/Dec
Vol. 48
Issue 10
Pg. 1329-1333
ISSN: 1536-4828 [Electronic] United States |
PMID | 31688597
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.)
|
Chemical References |
|
Topics |
- Adult
- Enoxaparin
(therapeutic use)
- Female
- Heparin
(therapeutic use)
- Humans
- Islets of Langerhans Transplantation
(adverse effects)
- Male
- Middle Aged
- Pancreatectomy
(adverse effects)
- Portal Vein
- Postoperative Complications
(prevention & control)
- Retrospective Studies
- Transplantation, Autologous
- Venous Thrombosis
(prevention & control)
|